Skip to main content
. 2021 Dec 2;12:772941. doi: 10.3389/fimmu.2021.772941

Figure 3.

Figure 3

Treatment with a TRPV4 antagonist alleviated the dry skin symptoms of AEW-treated mice. (A) A schematic illustration depicting the administration of HC067047 (HC067) during treatment with AEW. (B) Pretreatment with HC067 alleviated the deterioration in the overall skin conditions following AEW treatment. (C) The skin lesion scores significantly reduced in the HC067-treated AEW mice on day 5 (n = 6). (D) Representative H&E-stained images of the skin lesions of AEW-treated mice with or without HC067 administration. (E) The thickness of the epidermis significantly decreased in the skin lesions of the HC067-treated AEW mice (n = 6), compared to that of the control (n = 6) (F) The values of TEWL significantly reduced in the HC067-treated AEW mice on day 5 (n = 9), compared to those of the control (n = 9). (G) The spontaneous scratching bouts were reduced in the HC067-treated AEW mice (n = 5), compared to those of the control (n = 6). (H) The serum levels of TSLP significantly decreased in the HC067-treated AEW mice (n = 6), compared to those of the control (n = 6). (I) TSLP in the skin significantly decreased in HC067-treated AEW mice (n = 6) compared to the AEW-treated mice (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001.